Stryker Corporation (SYK) — Q2 2026 Earnings Preview
Prepared: July 29, 2026 Earnings Date: July 30, 2026 (After Market Close) Reporting Period: Q2 2026 (April – June 2026)
1. Earnings Preview
Key Takeaway: The setup into Q2 2026 is constructive — consensus is a recoverable bar after the Q1 cyber-disruption, and the single biggest swing factor is the pace and completeness of the revenue catch-up that management guided toward Q2 (revenue recognition) and the back half (capital equipment and procedure rescheduling).
Heading into Q2 2026, the bar for Stryker is shaped almost entirely by the cyber-incident recovery narrative rather than underlying demand, which management has consistently described as healthy. Consensus organic growth of ~9.3% for Q2 represents a meaningful step-up from Q1's disrupted 2.4%, and management explicitly guided that Q2 would capture the revenue recognition catch-up from deferred orthopaedic procedures — making the quarter a critical proof point that the recovery is on track. Guidance tone has been stable-to-improving since the April 30 print: at the May Bank of America conference, management confirmed Q2 was tracking in line with internal plans, expressed comfort with where Street consensus sat, and noted that favorable tariff developments (rate reductions since initial guidance) were partially offsetting cyber-related cost pressures within the full-year guide. Estimate revisions have been modest and directionally positive since the Q1 print — the Q2 organic growth consensus moved from ~9.4% to ~9.3% and FY 2026 EPS consensus is essentially flat at ~$14.98 vs. the $14.98 post-Q1 baseline — suggesting the Street has largely accepted management's recovery framework without adding incremental risk. The stock has recovered sharply from its post-Q1 lows (~$282 trough in mid-May) to ~$352 as of July 28, outperforming IHI (+4%) and SPY (+3%) by a wide margin since the April 30 earnings date, implying the market has already priced in a clean recovery quarter; the key wildcard is whether capital equipment shipments (beds, stretchers, defibrillators — the longer-cycle MedSurg items) have cleared the production backlog fast enough to show up in Q2 revenue, or whether that recovery remains weighted to Q3/Q4 as originally guided.
2. KPIs & Consensus Expectations
Key Takeaway: Consensus sets a recoverable but meaningful bar — organic growth of ~9.3% vs. Q1's disrupted 2.4% is the critical proof point; adjusted EPS of $3.47 is the bigger swing factor given tariff headwinds and manufacturing absorption uncertainty still lingering from the cyber incident.
Table 1 — Q2 2026 Current Quarter Snapshot (All Key KPIs)
KPI | Q1 2026 Actual (Last Quarter) | Q2 2025 Actual (Prior Year) | Q2 2026 Consensus Estimate | YoY Change | FY 2026 Guidance | Consensus vs. Guidance Midpoint |
Total Revenue ($B) | $6.02B | $6.02B | $6.57B | +9.1% YoY | Organic growth 8.0–9.5% | ~+0.1% above midpoint |
Organic Revenue Growth (%) | 2.4% | 10.2% | 9.3% | -90 bps vs. PY | 8.0–9.5% (FY) | Within range |
Adjusted EPS (Diluted Operating) | $2.60 | $3.13 | $3.47 | +10.9% YoY | $14.90–$15.10 (FY) | ~-0.3% below midpoint |
Adj. Gross Profit ($B) | $3.83B (63.6% margin) | $3.93B (65.3% margin) | $4.28B | +8.9% YoY | 150 bps expansion (3-yr target) | N/A — FY target |
Adj. Operating Income ($B) | $1.27B (21.1% margin) | $1.55B (25.7% margin) | $1.70B | +10.1% YoY | Margin expansion vs. 2025 | N/A — FY target |
MedSurg & Neurotech Revenue ($B) | $3.21B | $3.31B | $3.62B | +9.5% YoY | N/A — segment | N/A |
Orthopaedics Revenue ($B) | $2.81B | $2.72B | $2.95B | +8.6% YoY | N/A — segment | N/A |
Mako Installations (Units) | 77 units (record Q1) | 90 units | 98 units | +8.9% YoY | Sustained momentum guided | N/A |
Sources: Visible Alpha Consensus and Actuals Data. Q2 2026 consensus as of July 29, 2026. Q1 2026 actuals as reported April 30, 2026. Prior year Q2 2025 actuals as reported. Segment revenue (MedSurg & Neurotech, Orthopaedics) note: VA historical segment labels differ from current reporting structure following the June 2026 Ortho Tech recast; figures shown reflect the closest available comparable.
Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)
KPI 1: Total Revenue
Quarter | Reported ($B) | Consensus ($B) | Surprise % | Result |
Q1 2026 | $6.02B | $6.34B | -5.0% | Miss |
Q4 2025 | $7.17B | $7.11B | +0.8% | Beat |
Q3 2025 | $6.06B | $6.03B | +0.5% | Beat |
Q2 2025 | $6.02B | $5.93B | +1.5% | Beat |
Q1 2025 | $5.87B | $5.68B | +3.3% | Beat |
Q4 2024 | $6.44B | $6.35B | +1.4% | Beat |
Q3 2024 | $5.49B | $5.37B | +2.2% | Beat |
Q2 2024 | $5.42B | $5.41B | +0.3% | Beat |
Pattern: SYK beat revenue consensus in 7 of the last 8 quarters, with the sole miss being Q1 2026 due to the cyberattack disruption; the pre-cyber beat rate was 100% over the prior 7 quarters, averaging ~+1.7% upside.
KPI 2: Adjusted EPS (Diluted Operating)
Quarter | Reported ($) | Consensus ($) | Surprise % | Result |
Q1 2026 | $2.60 | $2.99 | -13.0% | Miss |
Q4 2025 | $4.47 | $4.40 | +1.6% | Beat |
Q3 2025 | $3.19 | $3.14 | +1.6% | Beat |
Q2 2025 | $3.13 | $3.07 | +2.0% | Beat |
Q1 2025 | $2.84 | $2.72 | +4.4% | Beat |
Q4 2024 | $4.00 | $3.87 | +3.4% | Beat |
Q3 2024 | $2.87 | $2.76 | +3.9% | Beat |
Q2 2024 | $2.82 | $2.79 | +1.0% | Beat |
Pattern: SYK beat adjusted EPS consensus in 7 of the last 8 quarters (sole miss: Q1 2026 cyberattack), with a pre-cyber average beat of ~+2.6%; the consistent beat cadence sets a high bar for Q2 2026 to re-establish the pattern.
Source: Visible Alpha Consensus and Actuals Data.
3. Guidance & Commentary Evolution
Key Takeaway: Full-year guidance has been fully reaffirmed since Q1 earnings with no numerical changes; the only post-earnings update was management's May conference commentary confirming Q2 is tracking to plan and that favorable tariff developments are partially offsetting cyber-related cost pressures — a modestly positive tone shift.
Metric | Initial Guidance (Q1 2026 Earnings Call, Apr 30) | Revised Guidance | Current Consensus | Note |
FY 2026 Organic Revenue Growth | 8.0% – 9.5% | — | ~8.8% | Reaffirmed; no change. May conference: Q2 tracking to plan, recovery cadence intact. |
FY 2026 Adjusted EPS | $14.90 – $15.10 | — | ~$14.98 | Reaffirmed; reflects expected sales recovery, operational excellence, and anticipated tariff improvements. |
FY 2026 Adj. Other Income & Expense | ~$420M | — | N/A | Unchanged. |
FY 2026 Effective Tax Rate | 15% – 16% | — | N/A | Unchanged. |
Operating Margin (3-yr target) | +150 bps through 2028 | — | N/A | Unchanged; Q1/Q2 tariff headwinds acknowledged but full-year margin expectations intact. |
Tariff Outlook | Headwinds in Q1/Q2 vs. prior year; anticipated improvements embedded in EPS guide | ↑ Improved (May conference) | N/A | ↑ Favorable tariff rate reductions since initial guidance partially offset cyber costs; company participating in government tariff refund process. |
Mako Installations | Sustained momentum guided; Mako Shoulder full launch on Mako 4 mid-year | — | 98 units (Q2 consensus) | Record Q1 installations; Mako 4 uptake strong; Shoulder launch expected mid-2026. |
4. Guidance vs. Estimate Revision Tracker
Key Takeaway: Estimates have been remarkably stable since the Q1 print — Q2 organic growth consensus is essentially flat vs. the post-Q1 baseline and FY 2026 EPS consensus is unchanged at ~$14.98 — suggesting the Street has fully accepted management's recovery framework; the gap between consensus and guidance midpoint is minimal, leaving little cushion if the recovery cadence disappoints.
KPI (Period) | Estimate ~5 Days Post Q1 Earnings (as of May 5, 2026) | Current Consensus (Jul 29, 2026) | Estimate Δ (%) | Initial Guidance (Q1 Call) | Current Guidance | Guidance Δ | Consensus vs. Guidance (%) |
Total Revenue — Q2 2026 | $6.577B | $6.571B | -0.1% | No quarterly guidance | No quarterly guidance | N/A | N/A |
Organic Growth % — Q2 2026 | ~9.4% | ~9.3% | -0.1 pp | No quarterly guidance | No quarterly guidance | N/A | N/A |
Adj. EPS — Q2 2026 | $3.477 | $3.475 | -0.1% | No quarterly guidance | No quarterly guidance | N/A | N/A |
Total Revenue — FY 2026 | $27.283B | $27.270B | -0.1% | Organic growth 8.0–9.5% | Unchanged | None | ~+0.1% above midpoint |
Organic Growth % — FY 2026 | ~8.83% | ~8.81% | -0.02 pp | 8.0–9.5% | Unchanged | None | Within range; near midpoint |
Adj. EPS — FY 2026 | $14.981 | $14.980 | ~0.0% | $14.90–$15.10 | Unchanged | None | -0.1% below midpoint ($15.00) |
Estimates have barely moved since the Q1 print, reflecting the Street's confidence in management's recovery framework. The near-zero revision delta across all KPIs means there is limited estimate cushion — a clean Q2 recovery is already in the price; any shortfall in the capital equipment catch-up (guided to Q3/Q4) could pressure the FY guide.
Source: Visible Alpha Consensus and Actuals Data. As-of date May 5, 2026 used as post-Q1 earnings baseline.
5. Stock Performance
Key Takeaway: SYK has dramatically outperformed since Q1 earnings — up ~+12% vs. IHI (iShares U.S. Medical Devices ETF) +4% and SPY +3% — driven almost entirely by multiple re-expansion as the market priced in a successful cyber recovery; the stock has re-rated from ~$282 trough (mid-May) to ~$352, meaning the recovery is largely priced in and Q2 execution must now validate the move.
SYK vs. IHI (iShares U.S. Medical Devices ETF) vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings Date (April 30, 2026). Source: Stock Price Data.
Sector ETF: IHI (iShares U.S. Medical Devices ETF) — appropriate sub-sector benchmark for Stryker as a large-cap medical device company. Key events marked: June 26, 2026 Ortho Tech segment recast 8-K filing.
- Post-Q1 earnings (May 1): SYK fell ~-6.5% the day after earnings (Apr 30 close $315 → May 1 close $295) as the market digested the cyber miss, but management's guidance reaffirmation limited the damage.
- May trough (~May 11, $283): SYK hit its post-earnings low as the market assessed the depth of the cyber disruption; IHI and SPY were broadly stable, indicating SYK-specific pressure.
- May recovery (May 12–May 20): SYK rallied ~+14% from trough to ~$321 as management's May Bank of America conference commentary confirmed Q2 was tracking to plan and tariff headwinds were easing.
- June 26 Ortho Tech 8-K: SYK surged ~+5% on the day of the segment recast filing, likely reflecting positive investor reception to the strategic clarity of the new Ortho Tech business unit combining Mako and enabling technologies.
- July rally (Jul 2–Jul 28): SYK continued to grind higher to ~$347, outpacing IHI and SPY, as the market priced in a clean Q2 recovery ahead of the July 30 print.
6. Material News & Developments
Key Takeaway: The most important development since Q1 earnings is management's May conference confirmation that Q2 is tracking to plan — the single most direct read-through for the print; the Amplitude Vascular Systems acquisition close and Ortho Tech recast are strategically significant but not near-term earnings drivers.
- May 7, 2026 — Amplitude Vascular Systems acquisition closed: Stryker completed the acquisition of Amplitude Vascular Systems (IVL technology for calcified peripheral artery disease), expanding its cardiovascular footprint. Management described this as a 'turbo booster' for the Inari peripheral vascular platform serving the same call point. Implication: Modest near-term revenue contribution; strategically important for the cardiovascular adjacency build-out.
- May 8, 2026 — Annual shareholder meeting: Shareholders backed directors, executive pay, and auditor without controversy. No material governance developments.
- May 2026 — Bank of America Global Healthcare Conference: Management provided the three-bucket cyber recovery framework (revenue recognition in Q2; capital equipment production catch-up in H2; procedure rescheduling spread Q2–Q4). Confirmed Q2 tracking to internal plans and expressed comfort with Street consensus. Tariff environment described as more favorable than initial guidance assumed. Capital order backlog continues to grow with orders outpacing shipments. Implication: Most direct positive read-through for Q2 print; management effectively pre-cleared the quarter.
- June 26, 2026 — Ortho Tech segment recast 8-K: Stryker filed an 8-K recasting three years of financial statements to reflect the new Ortho Tech business unit (combining orthopaedic instruments from Instruments with Mako and enabling technologies from Other Orthopaedics). The two primary segments remain MedSurg & Neurotechnology and Orthopaedics. Implication: Improves transparency on Mako economics; Q2 will be the first quarter reported under the new structure, creating some comparability complexity.
- July 1, 2026 — Q2 2026 earnings announcement date confirmed: Stryker confirmed July 30, 2026 after-market-close earnings release with 4:30 PM ET webcast.
- Ongoing — Mako 4 and Mako Shoulder launch: Management guided for full Mako Shoulder launch on Mako 4 mid-year 2026. Surgeon feedback on revision hip described as a 'cheat code.' Implication: Mako installations in Q2 (consensus: 98 units) will be a key indicator of whether the mid-year launch is gaining traction.
- Ongoing — Incompass Total Ankle and PROPHECY cut guides: Broad ankle adoption gated on pending FDA clearance of PROPHECY cut guides, described as in final stages. Expanded reimbursement for total ankle procedures already in place. Implication: Potential positive catalyst if clearance arrives in Q2/Q3.
- Ongoing — Pangea European approval: Received European regulatory approval slightly ahead of schedule, adding a multi-year international growth tailwind expected to extend into 2027–2028.
- Ongoing — Tariff environment: Rate reductions since initial guidance are partially offsetting cyber-related cost pressures. Company participating in government tariff refund process (IEEPA). Implication: Modest tailwind to Q2 gross margin vs. initial expectations; peers BSX and ISRG both disclosed IEEPA tariff refund benefits in Q2 2026.
7. Insider Transaction Activity
Key Takeaway: Insider activity since Q1 earnings is dominated by sales, with the most notable being a large discretionary open-market sale by Director Ronda Stryker (310,000 shares, ~$88M) — notable in size but not unusual given her long-term holding; no open-market buys were filed, which is a mild negative signal but not alarming given the stock's sharp recovery.
Name | Title | Transaction Type | Shares | Est. Value | Transaction Date | Note |
Ronda E. Stryker | Director | Open Market Sale | 310,000 | ~$88M (est. ~$284/sh) | May 26, 2026 | Discretionary sale via Revocable Trust; large in absolute size but Stryker family retains ~2.6M shares post-sale. No 10b5-1 plan disclosed. |
M. Kathryn Fink | VP, Chief HR Officer | Open Market Sale | 5,220 | ~$1.5M (est. ~$285/sh) | May 11, 2026 | Discretionary sale (direct). No 10b5-1 plan disclosed. |
M. Kathryn Fink | VP, Chief HR Officer | Open Market Sale | 3,500 | ~$1.0M (est. ~$285/sh) | May 11, 2026 | Discretionary sale via 2023 Mary Fink Living Trust. No 10b5-1 plan disclosed. |
Robert S. Fletcher | VP, Chief Legal Officer | 10b5-1 Planned Sale | 4,544 | ~$1.3M (est. ~$285/sh) | May 28, 2026 | Pre-planned 10b5-1 sale; routine/obligation-driven. Retains 10,582 shares post-sale. |
Source: SEC Form 4 Filings. All transactions filed May 2026. No open-market buys were filed in the period. Estimated values based on approximate transaction-date stock prices.
8. Peer Commentaries — Q2 2026 Read-Through
Key Takeaway: Peer Q2 2026 reports are broadly constructive for SYK — hospital capital equipment demand remained healthy (ISRG strong capital quarter; GMED large pipeline), procedure volumes held up despite ACA/Medicaid noise (ABT explicitly dismissed the risk for medtech), and tariff refunds (IEEPA) provided a gross margin tailwind that SYK should also benefit from; the one cautionary note is ISRG flagging modest U.S. procedure softness in deferrable categories, which could read through to elective orthopaedic volumes.
Scope: Only commentary about the April–June 2026 calendar quarter (SYK's Q2 2026) is included. Peer Q1 2026 results commentary about prior-quarter performance is excluded. MDT commentary covers its Q1 FY2027 guidance (April–June 2026 period). GMED commentary covers its Q2 2026 forward outlook provided on the Q1 2026 earnings call (May 7, 2026).
Boston Scientific (BSX) — Q2 2026 Earnings (Reported July 29, 2026)
Read-Through Signal: Broadly positive for SYK.
Theme | BSX Commentary | SYK Read-Through |
Overall Q2 Performance | Net sales of $5.44B, +7.0% organic, beating guidance of 5–7%. Adj. EPS $0.86 vs. $0.82–$0.84 guidance. CEO: 'delivered a solid quarter while continuing to navigate a dynamic environment.' | Positive: Broad medtech demand held up in Q2 despite macro uncertainty; a clean beat from a large-cap peer validates the market environment for SYK's recovery quarter. |
Hospital Capital Equipment | MedSurg segment grew +5.4% organically. No specific capital equipment demand commentary, but overall growth beat guidance. | Mildly positive: MedSurg growth in line with expectations suggests hospital capital budgets were not materially constrained in Q2. |
Tariff Impacts (IEEPA Refund) | BSX recognized an $83M IEEPA tariff refund in Q2 2026 gross profit, contributing $0.05/share benefit. Company lists 'changing trade and tariff policies' as ongoing risk. | Positive: SYK management noted participation in the government tariff refund process; BSX's $83M refund confirms the mechanism is real and material. SYK may disclose a similar benefit in Q2. |
Macro / Procedure Volumes | APAC grew +11.2%; LACA +16.2% operational. U.S. grew +6.2%. No specific ACA/Medicaid concern flagged. | Positive: Strong international growth and stable U.S. performance suggest no broad procedure volume deterioration in Q2. |
Abbott Laboratories (ABT) — Q2 2026 Earnings (Reported July 16, 2026)
Read-Through Signal: Positive for SYK, particularly on ACA/Medicaid volume concerns.
Theme | ABT Commentary | SYK Read-Through |
Overall Q2 Performance | Sales growth of 4.8%, accelerating vs. prior two quarters. Adj. EPS $1.31, exceeding guidance midpoint and consensus. FY guidance reaffirmed; EPS raised to $5.45–$5.60. | Positive: Acceleration in growth and guidance raise from a diversified medtech/diagnostics peer signals a healthy Q2 environment. |
ACA / Medicaid Volume Risk | ABT explicitly called ACA/Medicaid disenrollment concerns a 'flawed assumption' for medtech. Key argument: medtech did not see a spike in demand when ACA expanded, so it should not see a downside from disenrollment. Medicare (not Medicaid) is by far the largest U.S. payer for devices (>2/3 of U.S. cardio business). Demand for high-acuity, life-saving products is 'very inelastic.' Diagnostic test volumes held up in states with highest ACA disenrollment. | Strongly positive: SYK's orthopaedic and surgical procedures are predominantly Medicare-reimbursed (joint replacements, spine). ABT's framework directly supports the view that ACA/Medicaid noise should not materially impact SYK's Q2 procedure volumes. |
Hospital Demand / Macro | Hospital labs business grew +13% in Q2. Diagnostic test volumes reflect 'strong and stable demand for healthcare.' Aging population dynamic described as a durable secular tailwind. 'Healthcare demand is just going to continue to accelerate.' | Positive: Strong hospital lab demand and stable diagnostic volumes suggest hospital budgets and patient volumes were healthy in Q2 — supportive of SYK's capital equipment and procedure recovery. |
Gross Margin / Pricing | Adj. gross margin 58.0%, +100 bps YoY, driven by favorable business mix and operational improvements. No tariff headwind flagged. | Neutral: ABT's margin expansion is mix-driven (Exact Sciences addition); limited direct read-through to SYK's tariff-impacted gross margin trajectory. |
Edwards Lifesciences (EW) — Q2 2026 Earnings (Reported July 23, 2026)
Read-Through Signal: Positive for SYK on procedure volumes and hospital environment; limited direct orthopaedic read-through.
Theme | EW Commentary | SYK Read-Through |
Overall Q2 Performance | Total sales of $1.74B, +12.5% YoY, stronger than expected. Adj. EPS $0.78. Full-year sales guidance raised to 10–11% growth. TAVR sales +10.5%; TMT +44.8%. | Positive: Strong beat and guidance raise from a cardiovascular-focused medtech peer confirms robust procedure demand in Q2. |
Procedure Volumes | Global TAVR procedural growth benefited from 'sustained clinical momentum.' Mitral and tricuspid procedural growth remained in double digits. Surgical sales +5%. TAVR market described as 'still under-penetrated and under-adopted.' | Positive: Strong cardiovascular procedure volumes in Q2 suggest hospital OR capacity and patient scheduling were not materially disrupted — supportive of SYK's orthopaedic procedure rescheduling recovery. |
Pricing | Average selling prices for TAVR were 'stable globally.' No pricing pressure flagged outside of FX. | Positive: Stable pricing in cardiovascular supports SYK's expectation of 'modestly positive pricing impact' for the year. |
Gross Margin / Tariffs | Adj. gross margin 77.6%, flat YoY. FX reduced gross margin by 70 bps. No tariff impact mentioned. | Neutral: EW's margin profile is structurally different from SYK; limited direct read-through on tariff dynamics. |
Intuitive Surgical (ISRG) — Q2 2026 Earnings (Reported July 16, 2026)
Read-Through Signal: Mixed — strong capital equipment demand is positive for SYK; U.S. procedure softness in deferrable categories is a cautionary note.
Theme | ISRG Commentary | SYK Read-Through |
Hospital Capital Equipment Demand | Q2 described as a 'strong capital quarter.' 468 Da Vinci systems placed (+24% in U.S.). U.S. capital environment 'stable.' ~70% of U.S. systems acquired under leasing, providing flexibility for capital-constrained hospitals. Da Vinci 5 upgrade cycle driving strong demand. | Positive: Strong robotic capital equipment demand in Q2 is a direct positive read-through for SYK's Mako installations (consensus: 98 units) and capital equipment backlog clearance. |
U.S. Procedure Volumes (Cautionary) | U.S. Da Vinci procedure growth moderated to 12% in Q2 from 14% in Q1, 'predominantly in procedures that can be deferred.' Customer conversations suggest ACA premium subsidy expiration may be affecting when patients seek care. U.S. bariatric cases declined high single digits (GLP-1 impact). | Cautionary: Softness in deferrable U.S. procedures could read through to elective orthopaedic volumes (knee/hip replacements are deferrable). However, SYK's Q2 is already a recovery quarter from the cyber disruption, so the baseline comparison is different. |
ACA / Medicaid | ACA enrollment trends have 'not yet impacted' ISRG's capital pipeline. Significant portion of procedure business is private pay or commercial insurance; Medicare and Medicaid represent lower proportions. Underlying disease burden unchanged — deferred conditions will ultimately require treatment. | Mildly positive: Capital pipeline unaffected; deferred procedures will return. Consistent with ABT's view that medtech is less exposed to ACA dynamics than feared. |
Tariff Impacts (IEEPA Refund) | ISRG recognized a $36M pre-tax IEEPA tariff refund in Q2 2026. Excluding this, Q2 non-GAAP gross margin would have been 68.7% vs. reported 70.0%. Full-year gross margin forecast had previously reflected 100 bps tariff impact. | Positive: Confirms IEEPA refund mechanism is active and material across medtech. SYK's participation in the government tariff refund process (noted at May conference) should yield a similar benefit in Q2. |
Medtronic (MDT) — Q4 FY2026 Earnings (Reported May 20, 2026) — Q1 FY2027 Guidance (April–June 2026)
Read-Through Signal: Positive for SYK on procedure volumes and orthopaedic/spine market; tariff headwind is a cautionary note.
Theme | MDT Commentary (Q1 FY2027 Guidance = Apr–Jun 2026) | SYK Read-Through |
Organic Growth Outlook (Apr–Jun 2026) | MDT guided Q1 FY2027 organic growth of ~11.5–12% (includes ~500–600 bps benefit from an extra selling week). Underlying organic growth ex-extra week is ~6–7%, consistent with FY2027 guidance of 6.75–7.25%. | Positive: MDT's confidence in mid-to-high single-digit underlying organic growth for the April–June period supports a healthy medtech demand environment for SYK's recovery quarter. |
Orthopaedic / Spine Market | Cranial and Spinal Technologies grew 3% in both U.S. and international. Core Spine gained share, growing 6% on ModuleX expansion and distributor conversions. Stealth AXiS navigation platform received FDA clearance across spine, cranial, and ENT; early commercial launch 'progressing well' with 'very positive' physician feedback. Robotics penetration still in 'high single digits' with 'significant runway ahead.' | Positive: Healthy spine/orthopaedic market conditions and low robotics penetration validate SYK's Mako growth runway. MDT's navigation success (Stealth AXiS) is a competitive read-through but also confirms surgeon appetite for enabling technologies — a market SYK's Ortho Tech unit is targeting. |
Procedure Volumes | Simplicity (hypertension) doubled average weekly procedure volumes post-NCD. Hugo robotic procedure volume growth '2x to 3x the market.' TAVR weekly U.S. procedure volumes 'stabilized over the last 8 weeks.' Macro backdrop: 'People are living longer, chronic disease is rising and the demand for medical procedures will only grow.' | Positive: Broad procedure volume growth across MDT's portfolio for the April–June period supports SYK's expectation of procedure rescheduling recovery in Q2. |
Tariff Headwind (Cautionary) | MDT guided $250M total FY2027 tariff impact to COGS, including $75M in Q1 FY2027 (Apr–Jun 2026). This is $65M higher than prior year. MDT did NOT factor in any government refunds in guidance, taking a 'status quo' approach. Tariff environment described as 'still a little volatile.' | Cautionary: MDT's $75M Q1 FY2027 tariff headwind (without refund benefit) is a reminder that tariffs remain a real gross margin drag. SYK faces similar headwinds in Q2 2026, though management has guided for 'anticipated improvements in the tariff outlook' and is participating in the refund process. |
Globus Medical (GMED) — Q1 2026 Earnings (Reported May 7, 2026) — Q2 2026 Forward Outlook
Read-Through Signal: Mixed — healthy orthopaedic/spine market and strong robot pipeline are positive; shift toward leases/rentals in capital equipment is a cautionary note for SYK's capital revenue recognition.
Theme | GMED Commentary (Q2 2026 Outlook, provided May 7) | SYK Read-Through |
Hospital Capital Equipment / Robot Pipeline | GMED described a 'large pipeline of deals' for Q2 and beyond in Enabling Technologies (robotic systems). However, the mix is shifting toward leases and rentals vs. outright sales, which reduces upfront revenue recognition. This shift is a response to the 'changing CapEx environment and increased competition.' | Mixed: Large robot pipeline is positive for SYK's Mako demand. The lease/rental shift is a cautionary note — if hospital CapEx budgets are tightening, SYK's capital equipment shipment recovery (beds, stretchers, Mako) could face headwinds in Q2, with more revenue pushed to H2. |
Orthopaedic Market Conditions | Trauma business grew +30.4% YoY in Q1 2026, driven by share gains in core trauma and Precice Limb Lengthening. U.S. Spine market growing ~3% overall; GMED's growth is primarily share gains. ExcelsiusGPS used in almost 130,000 robotic procedures to date. | Positive: Healthy orthopaedic and spine market conditions with share gains confirm the underlying market is growing. SYK's Mako-driven knee/hip business should benefit from the same healthy demand environment. |
Q2 2026 Revenue Cadence | GMED expects a 'typical revenue cadence with a step-up in Q2' following the sequential step-down from Q4 to Q1. New FDA 510(k) clearances received early Q2 for patient-specific spacer systems. Demand for ANTHEM Elbow plating system 'continues to exceed expectations.' | Positive: Seasonal step-up in Q2 is consistent with SYK's own recovery narrative. New product momentum in orthopaedics supports the view that the market environment is favorable for SYK's Q2 recovery. |
Macro / Procedure Volumes | Small impact from weather and Kaiser strike in Q1 2026 but company 'comfortable with performance.' No material geopolitical revenue risk. Utilization environment described as stable. | Positive: Stable utilization and no macro-driven volume disruption in the orthopaedic/spine market is directly supportive of SYK's procedure rescheduling recovery in Q2. |
Peer Read-Through Summary
Peer | Signal | Key Takeaway for SYK Q2 2026 |
BSX (Q2 2026) | Positive | Solid medtech demand; IEEPA tariff refund ($83M) confirms mechanism SYK is participating in; no capital equipment demand concerns. |
ABT (Q2 2026) | Positive | Explicitly dismissed ACA/Medicaid volume risk for medtech; Medicare is the dominant payer for devices; hospital demand strong and stable. |
EW (Q2 2026) | Positive | Strong procedure volumes across cardiovascular; stable pricing; guidance raised — confirms healthy Q2 procedure environment. |
ISRG (Q2 2026) | Mixed | Strong capital quarter (positive for Mako); U.S. deferrable procedure softness (cautionary for elective ortho); IEEPA refund ($36M) confirms tariff benefit for SYK. |
MDT (Q1 FY2027 Guidance, Apr–Jun 2026) | Positive | Healthy spine/ortho market; robotics penetration still low (runway for Mako); procedure volumes growing; tariff headwind ($75M in quarter) is a cautionary note. |
GMED (Q2 2026 Outlook, May 7) | Mixed | Large robot pipeline and healthy ortho market (positive); shift to leases/rentals in capital equipment suggests CapEx budget pressure (cautionary for SYK's capital shipment recovery). |
—
Disclosures & Sources: Financial estimates and actuals sourced from Visible Alpha Consensus and Actuals Data. Stock price data sourced from Yahoo Finance via Stock Price Data dataset. Insider transaction data sourced from SEC Form 4 Filings Database. Peer commentary sourced from company earnings call transcripts and earnings releases (BSX Q2 2026, ABT Q2 2026, EW Q2 2026, ISRG Q2 2026, MDT Q4 FY2026, GMED Q1 2026) via financial documents database. This document is prepared for informational purposes only and does not constitute investment advice. Prepared: July 29, 2026.